The Financial

Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment

The FINANCIAL — Novartis on December 8 announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...
Pharmabiz

Novartis' Ultibro Breezhaler significantly improved COPD patients' lung function after direct switch from Seretide

Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD ...
FiercePharma

Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide®*

Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide® Once-daily Ultibro® Breezhaler® reduced exacerbations (flare ups) by 31% ...
Business Wire

Sosei Group Announces Positive Results for Ultibro® and Seebri® Presented at ERS 2014, and Promotion Agreement with Pfizer in the UK

Analyses from the QUANTIFY study demonstrated that Ultibro ® Breezhaler ® significantly improved lung function and shortness of breath in patients with moderate-to-severe COPD, compared to the ...
Finanznachrichten

Major study published in NEJM confirms Novartis' Ultibro(R) Breezhaler(R) superiority over Seretide(R) in preventing COPD exacerbations

Results confirmed that Ultibro Breezhaler 110/50 mcg met its primary endpoint (non-inferiority) and furthermore demonstrated superiority to SFC 50/500 mcg on the rate of all COPD exacerbations ...
Pharmabiz

Study shows Novartis' Ultibro Breezhaler improved cardiac function in COPD patients with lung hyperinflation

Novartis has announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler ...
FierceBiotech

Novartis announces positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...
Monthly Prescribing Reference

Study Shows Direct Switch to Ultibro Breezhaler Improves COPD Symptoms

Novartis announced positive data from the CRYSTAL study evaluating the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate chronic obstructive pulmonary ...
Nasdaq

Data on Novartis' Ultibro Breezhaler - Analyst Blog

Novartis ( NVS) announced positive data on Ultibro Breezhaler from the QUANTIFY study at the American Thoracic Society (ATS) International Conference. Novartis conducted this multicenter, randomized, ...
Nasdaq

Novartis' Ultibro Breezhaler Approved in Europe - Analyst Blog

Positive news flowed in at Novartis ( NVS) when its chronic obstructive pulmonary disease (COPD) drug, Ultibro Breezhaler, gained approval in Europe. Ultibro Breezhaler was approved as a once-daily ...
News Medical

Direct switch of COPD patients from Seretide to Novartis' Ultibro Breezhaler improves lung function

The superiority of once-daily Ultibro Breezhaler over twice-daily salmeterol/fluticasone in improving lung function and reducing the rate of COPD exacerbations has been established in previous studies ...
Business Insider

Novartis: Switching COPD Patients To Ultibro Breezhaler Improves Lung Function

(RTTNews) - Novartis (NVS) announced Monday positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive ...